Innate Pharma (IPHYF) 12.2621 $IPHYF Sanofi Ink
Post# of 273254
Posted On: 09/25/2016 1:03:56 PM
Innate Pharma (IPHYF) 12.2621 $IPHYF
Sanofi Inks Multiple Deals, Sarilumab under FDA Review
Zacks Equity Research - Zacks Investment Research - Mon Jan 11, 3:40PM CST
Sanofi (SNY) came up with important announcements on both the deal making and pipeline front.
ANIK: 46.92 (-1.07), SNY: 38.35 (-0.22), REGN: 410.39 (+2.38)
Should Innate Pharma (IPHYF) Be On Your Radar Now?
Zacks Equity Research - Zacks Investment Research - Fri Oct 09, 7:45AM CDT
Innate Pharma has seen a small price movement but large positive earnings estimate revisions make it an unappreciated stock that might have potential for gains
INNATE PHARMA : Fifth DSMB meeting of the EffiKIR trial recommends continuation without modification
GlobeNewswire - Mon Sep 14, 12:36AM CDT
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced that the Data and Safety Monitoring Board ("DSMB"
completed its fifth assessment of the EffiKIR study and recommended continuation of the trial without modification.
Presentation of IPH4102 rationale and Phase I protocol to be presented at the upcoming EORTC CTCL meeting
GlobeNewswire - Mon Sep 07, 12:33AM CDT
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced that Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris and co-discoverer of the target KIR3DL2, will present the rationale of IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody for the treatment of CTCL, as well as the protocol of the upcoming Phase I trial at the EORTC cutaneous lymphoma task force meeting (September 25-27, 2015 in Turin, Italy).
Head And Neck Cancer Squamous Cell Carcinoma: Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development and Enlists all Their Major and Minor Projects
M2 - Thu Aug 13, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dgdj8x/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities Companies Mentioned - AbbVie Inc. - Acceleron Pharma, Inc. - Advaxis, Inc. - Altor BioScience Corporation - Amgen Inc. - Ascenta Therapeutics, Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BIND Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CEL-SCI Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose Llc - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Genexine, Inc. - GlaxoSmithKline Plc - Gliknik, Inc. - Glycotope GmbH - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovative Therapies, Ltd. - Incyte Corporation - Innate Pharma SA - Inovio Pharmaceuticals, Inc. - Karyopharm Therapeutics, Inc. - Laboratoires Pierre Fabre SA For more information visit http://www.researchandmarkets.com/research/dg...d_and_neck.
IMMU: 3.27 (-0.03), ADXS: 10.80 (-0.18), CVM: 0.42 (+0.01), INCY: 88.98 (-0.29), CLDX: 3.83 (+0.11), IMGN: 2.82 (-0.05), AMGN: 174.80 (-0.82), LLY: 81.16 (-0.13), BIND: 0.78 (-0.09), GSK: 43.42 (-0.16), BMY: 56.48 (+0.06), INO: 9.50 (-0.24), AZN: 33.97 (-0.31), AVEO: 0.90 (+0.02), ABBV: 64.98 (-0.10), KPTI: 9.35 (-0.36), XLRN: 39.50 (-0.50)
Clearance of global agreement with AstraZeneca and receipt by Innate Pharma of $250m initial payment
GlobeNewswire - Tue Jul 07, 12:36AM CDT
CLEARANCE OF CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH ASTRAZENECA AND RECEIPT BY INNATE PHARMA OF $250M INITIAL PAYMENT
Global Cutaneous T-Cell Lymphoma Therapeutics Pipeline Review, H1 2015
M2 - Fri Jun 05, 5:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4hl8ss/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Affimed Therapeutics AG - Chipscreen Biosciences Ltd - Cornerstone Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - Galderma S.A. - Innate Pharma SA - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Neumedicines Inc. - Novartis AG - OncoSec Medical Inc. - Onyx Pharmaceuticals, Inc. - Sanofi - Soligenix, Inc. - Taiwan Liposome Company, Ltd. For more information visit http://www.researchandmarkets.com/research/4h...eous_tcell
JNJ: 118.81 (-0.65), CYCC: 5.62 (-0.20), ONCS: 1.78 (+0.01), NVS: 81.48 (-0.55), KPTI: 9.35 (-0.36)
AstraZeneca Inks Multiple Deals, Immuno-Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:43PM CDT
AstraZeneca's (AZN) global biologics research and development arm, MedImmune, inked deals with Innate Pharma, Celgene and Juno related to its anti-PD-L1 immune checkpoint inhibitor, MEDI4736.
AZN: 33.97 (-0.31), JUNO: 30.11 (-0.51), CELG: 109.43 (-1.14)
Cutaneous T-Cell Lymphoma Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 07, 11:05AM CDT
The report "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-cell lymphomas (CTCLs) are a group of disorders characterized by abnormal accumulation of malignant T-cells in the skin potentially resulting in the development of rashes, plaques and tumors. Cutaneous T cell lymphoma (CTCL) has four stages of progression: patch stage, plaque stage, tumor stage, and erythroderma stage. The disease can manifest at any stage and does not necessarily go through an orderly progression. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cutaneous-t-...eport.html
JNJ: 118.81 (-0.65), CYCC: 5.62 (-0.20), ONCS: 1.78 (+0.01), NVS: 81.48 (-0.55), KPTI: 9.35 (-0.36)
INNATE PHARMA : DSMB RECOMMENDS CONTINUATION OF EFFIKIR TRIAL WITH TWO ARMS
GlobeNewswire - Thu Mar 26, 1:36AM CDT
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announces that the Data and Safety Monitoring Board ("DSMB" completed its fourth assessment of the EffiKIR study and recommended to stop treatment in one arm and continue the trial with the remaining two arms as per protocol.
INNATE PHARMA: First Phase II trial with IPH2201 open in head and neck cancer
GlobeNewswire - Fri Dec 19, 12:41AM CST
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announced that the first Phase II trial of IPH2201, a first-in-class NKG2A checkpoint inhibitor, was opened at the Charite Comprehensive Cancer Center (CCCC), Berlin, Germany.
INNATE PHARMA announces its 2015 FINANCIAL CALENDAR as well as its participation in upcoming investor conferences
GlobeNewswire - Tue Dec 02, 12:34AM CST
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, announces today its tentative financial calendar for 2015, which is set as follows:
Sanofi Inks Multiple Deals, Sarilumab under FDA Review
Zacks Equity Research - Zacks Investment Research - Mon Jan 11, 3:40PM CST
Sanofi (SNY) came up with important announcements on both the deal making and pipeline front.
ANIK: 46.92 (-1.07), SNY: 38.35 (-0.22), REGN: 410.39 (+2.38)
Should Innate Pharma (IPHYF) Be On Your Radar Now?
Zacks Equity Research - Zacks Investment Research - Fri Oct 09, 7:45AM CDT
Innate Pharma has seen a small price movement but large positive earnings estimate revisions make it an unappreciated stock that might have potential for gains
INNATE PHARMA : Fifth DSMB meeting of the EffiKIR trial recommends continuation without modification
GlobeNewswire - Mon Sep 14, 12:36AM CDT
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced that the Data and Safety Monitoring Board ("DSMB"
completed its fifth assessment of the EffiKIR study and recommended continuation of the trial without modification. Presentation of IPH4102 rationale and Phase I protocol to be presented at the upcoming EORTC CTCL meeting
GlobeNewswire - Mon Sep 07, 12:33AM CDT
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced that Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris and co-discoverer of the target KIR3DL2, will present the rationale of IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody for the treatment of CTCL, as well as the protocol of the upcoming Phase I trial at the EORTC cutaneous lymphoma task force meeting (September 25-27, 2015 in Turin, Italy).
Head And Neck Cancer Squamous Cell Carcinoma: Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development and Enlists all Their Major and Minor Projects
M2 - Thu Aug 13, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dgdj8x/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities Companies Mentioned - AbbVie Inc. - Acceleron Pharma, Inc. - Advaxis, Inc. - Altor BioScience Corporation - Amgen Inc. - Ascenta Therapeutics, Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BIND Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CEL-SCI Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose Llc - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Genexine, Inc. - GlaxoSmithKline Plc - Gliknik, Inc. - Glycotope GmbH - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovative Therapies, Ltd. - Incyte Corporation - Innate Pharma SA - Inovio Pharmaceuticals, Inc. - Karyopharm Therapeutics, Inc. - Laboratoires Pierre Fabre SA For more information visit http://www.researchandmarkets.com/research/dg...d_and_neck.
IMMU: 3.27 (-0.03), ADXS: 10.80 (-0.18), CVM: 0.42 (+0.01), INCY: 88.98 (-0.29), CLDX: 3.83 (+0.11), IMGN: 2.82 (-0.05), AMGN: 174.80 (-0.82), LLY: 81.16 (-0.13), BIND: 0.78 (-0.09), GSK: 43.42 (-0.16), BMY: 56.48 (+0.06), INO: 9.50 (-0.24), AZN: 33.97 (-0.31), AVEO: 0.90 (+0.02), ABBV: 64.98 (-0.10), KPTI: 9.35 (-0.36), XLRN: 39.50 (-0.50)
Clearance of global agreement with AstraZeneca and receipt by Innate Pharma of $250m initial payment
GlobeNewswire - Tue Jul 07, 12:36AM CDT
CLEARANCE OF CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH ASTRAZENECA AND RECEIPT BY INNATE PHARMA OF $250M INITIAL PAYMENT
Global Cutaneous T-Cell Lymphoma Therapeutics Pipeline Review, H1 2015
M2 - Fri Jun 05, 5:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4hl8ss/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Affimed Therapeutics AG - Chipscreen Biosciences Ltd - Cornerstone Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - Galderma S.A. - Innate Pharma SA - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Neumedicines Inc. - Novartis AG - OncoSec Medical Inc. - Onyx Pharmaceuticals, Inc. - Sanofi - Soligenix, Inc. - Taiwan Liposome Company, Ltd. For more information visit http://www.researchandmarkets.com/research/4h...eous_tcell
JNJ: 118.81 (-0.65), CYCC: 5.62 (-0.20), ONCS: 1.78 (+0.01), NVS: 81.48 (-0.55), KPTI: 9.35 (-0.36)
AstraZeneca Inks Multiple Deals, Immuno-Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:43PM CDT
AstraZeneca's (AZN) global biologics research and development arm, MedImmune, inked deals with Innate Pharma, Celgene and Juno related to its anti-PD-L1 immune checkpoint inhibitor, MEDI4736.
AZN: 33.97 (-0.31), JUNO: 30.11 (-0.51), CELG: 109.43 (-1.14)
Cutaneous T-Cell Lymphoma Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 07, 11:05AM CDT
The report "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-cell lymphomas (CTCLs) are a group of disorders characterized by abnormal accumulation of malignant T-cells in the skin potentially resulting in the development of rashes, plaques and tumors. Cutaneous T cell lymphoma (CTCL) has four stages of progression: patch stage, plaque stage, tumor stage, and erythroderma stage. The disease can manifest at any stage and does not necessarily go through an orderly progression. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cutaneous-t-...eport.html
JNJ: 118.81 (-0.65), CYCC: 5.62 (-0.20), ONCS: 1.78 (+0.01), NVS: 81.48 (-0.55), KPTI: 9.35 (-0.36)
INNATE PHARMA : DSMB RECOMMENDS CONTINUATION OF EFFIKIR TRIAL WITH TWO ARMS
GlobeNewswire - Thu Mar 26, 1:36AM CDT
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announces that the Data and Safety Monitoring Board ("DSMB"
completed its fourth assessment of the EffiKIR study and recommended to stop treatment in one arm and continue the trial with the remaining two arms as per protocol. INNATE PHARMA: First Phase II trial with IPH2201 open in head and neck cancer
GlobeNewswire - Fri Dec 19, 12:41AM CST
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announced that the first Phase II trial of IPH2201, a first-in-class NKG2A checkpoint inhibitor, was opened at the Charite Comprehensive Cancer Center (CCCC), Berlin, Germany.
INNATE PHARMA announces its 2015 FINANCIAL CALENDAR as well as its participation in upcoming investor conferences
GlobeNewswire - Tue Dec 02, 12:34AM CST
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, announces today its tentative financial calendar for 2015, which is set as follows:
(0)
(0)Scroll down for more posts ▼